VLA15, a new global Lyme disease vaccine undergoes clinical trials

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F23%3A00577347" target="_blank" >RIV/60077344:_____/23:00577347 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S1473309923003122?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1473309923003122?via%3Dihub</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
VLA15, a new global Lyme disease vaccine undergoes clinical trials
Original language description
Lyme disease (Lyme borreliosis) is a tick-borne bacterial infection that occurs in the temperate climates of North America and Eurasia. Treatment with antibiotics is effective only in the early stages of infection. Although the first human Lyme disease vaccine (LYMErix by SmithKline Beecham, Pittsburgh, PA, USA) was marketed and distributed in the USA from 1998 until 2002, it was discontinued and no vaccine is currently available.1, 2, 3 In The Lancet Infectious Diseases, Nicole Bézay and colleagues report the results of a randomised, phase 1, clinical trial in healthy adults immunised with Valneva's novel, multivalent outer surface protein A (OspA) subunit vaccine called VLA15.4
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)